miRNAs in chronic myeloid leukemia: small molecules, essential function

References

• Morris CM. Chronic myeloid leukemia: cytogenetic methods and applications for diagnosis and treatment. Methods Mol Biol. 2011;730:33–61.
   PubMedGoogle Scholar
• Salesse S, Verfaillie C. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. Oncogene. 2002;21:8547–8559.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Dreyling M. Chronic myelogenous leukemia: ESMO Clinical Recommendations for the diagnosis, treatment and follow-up. Ann Oncol. 2008;19:ii63–ii64.
   PubMed Web of Science ®Google Scholar
• Radich J, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci. 2006;103:2794–2799.
   PubMed Web of Science ®Google Scholar
• Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002;107:76–94.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes J, Ravandi F, et al. Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia. Semin Hematol. 2013;50:271–283.
   PubMed Web of Science ®Google Scholar
• Bhamidipati P, Kantarjian H, Cortes J, et al. Management of imatinib-resistant patients with chronic myeloid leukemia. Ther Adv Hematol. 2012;4:103–117.
   Google Scholar
• Kawaguchi Y, Jinnai I, Nagai K, et al. Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells. Leukemia. 2001;15:590–594.
   PubMed Web of Science ®Google Scholar
• Von Bubnoff N, Duyster J. Chronic myelogenous leukemia: treatment and monitoring. Dtsch Arztebl Int. 2010;107:114–121.
   PubMed Web of Science ®Google Scholar
• Allan N, Shepherd P, Richards S. UK Medical Research Council randomized, multicentre trial of interferon-alpha n1 for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. Lancet. 1995;345:1392–1397.
   PubMed Web of Science ®Google Scholar
• Deininger M, O’Brien SG, Guilhot F, et al. International randomized study of interferon vs. STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood. 2009;114:1. Abstract 1126.
   PubMed Web of Science ®Google Scholar
• Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology. 2009;2009:461–476.
   Google Scholar
• Nowicki M, Pawlowski P, Fischer T, et al. Chronic myelogenous leukemia molecular signature. Oncogene. 2003;22:3952–3963.
   PubMed Web of Science ®Google Scholar
• Ohmine K, Ota J, Ueda M, et al. Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells. Oncogene. 2001;20:8249–8257.
   PubMed Web of Science ®Google Scholar
• Oehler V, Yeung K, Choi Y, et al. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood. 2009;114:3292–3298.
   PubMed Web of Science ®Google Scholar
• Lee R, Feinbaum R, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–854.
   PubMed Web of Science ®Google Scholar
• Friedman RC, Farh KK, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19:92–105.
   PubMed Web of Science ®Google Scholar
• Ciafre S, Galardi S. microRNAs and RNA-binding proteins. RNA Biol. 2013;10:934–942.
   PubMed Web of Science ®Google Scholar
• Valencia-Sanchez M. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20:515–524.
   PubMed Web of Science ®Google Scholar
• Slezak-Prochazka I, Durmus S, Kroesen B, et al. MicroRNAs, macrocontrol: regulation of miRNA processing. RNA. 2010;16:1087–1095.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang H, Tao K, et al. miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein. Exp Cell Res. 2013;319:1094–1101.
   PubMed Web of Science ®Google Scholar
• Xishan Z, Ziying L, Jing D, et al. MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia. Sci Rep. 2015;5:12460.
   PubMed Web of Science ®Google Scholar
• Liu Y, Song Y, Ma W, et al. Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia. Leukemia Res. 2013;37:349–356.
   PubMed Web of Science ®Google Scholar
• Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, et al. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein. Cancer Lett. 2015;356:597–605.
   PubMed Web of Science ®Google Scholar
• Hershkovitz-Rokah O, Modai S, Pasmanik-Chor M, et al. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment. Cancer Lett. 2015;360:245–256.
   PubMed Web of Science ®Google Scholar
• Joshi D, Chandrakala S, Korgaonkar S, et al. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients. Gene. 2014;542:109–112.
   PubMed Web of Science ®Google Scholar
• Venturini L, Battmer K, Castoldi M, et al. Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007;109:4399–4405.
   PubMed Web of Science ®Google Scholar
• Suresh S, McCallum L, Lu W, et al. MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML. J Cell Commun Signal. 2011;5:183–191.
   PubMed Web of Science ®Google Scholar
• Wang W, Pu Q, Lin X, et al. Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway. Leukemia Res. 2015;39:1117–1124.
   PubMed Web of Science ®Google Scholar
• Wang L, Liu Y, Beier U, et al. Foxp3+ T-regulatory cells require DNA methyltransferase 1 expression to prevent development of lethal autoimmunity. Blood. 2013;121:3631–3639.
   PubMed Web of Science ®Google Scholar
• Baskiewicz-Masiuk M, Machalinski B. The role of the STAT5 proteins in the proliferation and apoptosis of the CML and AML cells. Eur J Haematol. 2004;72:420–429.
   PubMed Web of Science ®Google Scholar
• Kaymaz B, Gunel N, Ceyhan M, et al. Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A. Tumor Biol. 2015;36:7915–7927.
   PubMed Web of Science ®Google Scholar
• Wang L, Li L, Li L, et al. MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors. Blood. 2014;125:1302–1313.
   PubMed Web of Science ®Google Scholar
• Fei J, Li Y, Zhu X, et al. miR-181a post-transcriptionally downregulates oncogenic RalA and contributes to growth inhibition and apoptosis in chronic myelogenous leukemia (CML). PLoS One. 2012;7:e32834.
   Google Scholar
• Mosakhani N, Mustjoki S, Knuutila S. Down-regulation of miR-181c in imatinib-resistant chronic myeloid leukemia. Mol Cytogenet. 2013;6:27.
   PubMed Web of Science ®Google Scholar
• Zimmerman E, Dollins C, Crawford M, et al. Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia. Mol Pharmacol. 2010;78:811–817.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Maruyama R, Yamamoto E, et al. DNA methylation and microRNA dysregulation in cancer. Mol Oncol. 2012;6:567–578.
   PubMed Web of Science ®Google Scholar
• Wong K, So C, Loong F, et al. Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One. 2011;6:e19027.
   PubMedGoogle Scholar
• Chim C, Wan T, Wong K, et al. Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms. J Trans Med. 2011;9:197.
   PubMed Web of Science ®Google Scholar
• Chim C, Wong K, Qi Y, et al. Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis. 2010;31:745–750.
   PubMed Web of Science ®Google Scholar
• Wong K, Yim R, Kwong Y, et al. Epigenetic inactivation of the MIR129-2 in hematological malignancies. J Hematol Oncol. 2013;6:16.
   PubMed Web of Science ®Google Scholar
• Chim C, Wong K, Leung C, et al. Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. J Cell Mol Med. 2011;15:2760–2767.
   PubMed Web of Science ®Google Scholar
• Li Y, Yuan Y, Tao K, et al. Inhibition of BCR/ABL protein expression by miR-203 sensitizes for imatinib mesylate. PLoS One. 2013;8:e61858.
   Google Scholar
• Bueno M, Perez de Castro I, Gomez de Cedron M, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008;13:496–506.
   PubMed Web of Science ®Google Scholar